DUBLIN, December 10, 2014 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/hzc93s/dendritic_cell) has announced the addition of the "Dendritic Cell and CAR-T Therapies, 2014 - 2024" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeutics including cell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
DCT makes use of autologous or allogenic Antigen Presenting Cells (APCs) to stimulate the immune system to recognise and act against the tumors. In April 2010, the FDA approval of Sipuleucel-T (PROVENGE, manufactured by Dendreon Corporation), a dendritic cell vaccine, gave a push to the concept of DCT. However, the vaccine hasn't been able to meet the high expectations. Despite this, the overall DCT outlook is promising; late stage development vaccines such as AGS-003, DCVax-L, DCVAC/PCa and Eltrapuldencel-T are likely to carry forward the baton.
With the similar aim to stimulate the body's immune system, CAR-T uses the patient's autologous effector T-cells, modifying it with a synthetic receptor enabling it to increase the tumor specific immune response. This therapy is expected to first enter market with the launch of CTL019 by Novartis in the next few years. In recent trials, CTL019 has shown complete remission in children with advanced cases of treatment-resistant ALL. Apart from Novartis, some other big pharmaceutical companies including Pfizer have entered the space. Juno Therapeutics, Takara Bio and Kite Pharma are other active players.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Cancer Therapeutics and Immuno-Oncology
4. Current Market Landscape
5. Dendritic Cell Therapy: Key Molecules and Future Outlook
6. Chimeric Antigen Receptor-T Cell Therapy
7. Company Profiles
8. Interview Transcripts
9. Conclusion
10. Appendix 1: Tabulated Data
11. Appendix 2: List of Companies and Organisations
Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/hzc93s/dendritic_cell
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article